Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer

Gene Therapy

Volumn 21, Issue 4, 2014, Pages 393-401

  Morris, J C ^a,b   Ramlogan Steel, C A ^a   Yu, P ^b   Black, B A ^a   Mannan, P ^b   Allison, J P ^c   Waldmann, T A ^b   Steel, J C ^a,b,d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE TRANSFER; GROWTH INHIBITION; IMMUNOGENETICS; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION; ANIMAL; BIOLOGICAL THERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; DENDRITIC CELL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TRANSPLANTATION; TUMOR CELL LINE; VACCINATION;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS;

ANIMALS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL- AND TISSUE-BASED THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; MALE; MICE; PROSTATIC NEOPLASMS; VACCINATION;

EID: 84897571963     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.10     Document Type: Article

References (41)

1. Keenan BP, Jaffee EM. Whole cell vaccines-past progress and future strategies. Semin Oncol 2012; 39: 276-286.
2. Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005; 12: 18-27.
3. Higano CS, Somer F, Curti B, Petrylak B, Drake D, Schnell C et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium 2009, LBA150.
4. Small ED, Gerritsen T, Rolland W, Hoskin F, Smith P, Parker D et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. ASCO Genitourinary Cancers Symposium 2009; 7.
5. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771-780.
6. + Tc1 responses in vivo. Eur J Immunol 2004; 34: 66-73.
7. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994; 13: 2822-2830.
8. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995; 14: 3654-3663.
9. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity 2002; 17: 537-547.
10. + T cell homeostasis. J Exp Med 2004; 200: 825-834.
11. Tarkowski M, Ferraris L, Martone S, Strambio de Castillia F, Misciagna D, Mazzucchelli RI et al. Expression of interleukin-15 and interleukin-15R alpha in monocytes of HIV type 1-infected patients with different courses of disease progression. AIDS Res Hum Retroviruses 2012; 28: 693-701.
12. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35-41.
13. Conlon KMJ, Janik J, Stewart D, Rosenberg SA, Worthy T, Fojo T et al. Phase I study of intravenous recombinant human interleukin-15 (rh IL-15) in adults with metastatic malignant melanoma and renal cell carcinoma. J Immunother 2012; 35: 102-103.
14. Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012; 72: 430-439.
15. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010; 16: 6019-6028.
16. Zhang M, Yao Z, Dubois S, Ju W, Muller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA 2009; 106: 7513-7518.
17. Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 2010; 17: 793-801.
18. Perera PY, Derrick SC, Kolibab K, Momoi F, Yamamoto M, Morris SL et al. A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. Vaccine 2009; 27: 2121-2127.
19. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci USA 2010; 107: 9843-9848.
20. Kraynyak KA, Kutzler MA, Cisper NJ, Laddy DJ, Morrow MP, Waldmann TA et al. Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther 2009; 20: 1143-1156.
21. Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res 2010; 70: 1072-1081.
22. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immu-notherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177: 6072-6080.
23. Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C et al. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 2010; 28: 1962-1974.
24. Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood 2012; 120: e1-e8.
25. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 2008; 283: 4189-4199.
26. Sandau MM, Schluns KS, Lefrancois L, Jameson SC. Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J Immunol 2004; 173: 6537-6541.
27. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 2010; 127: 85-92.
28. Hazama S, Noma T, Wang F, Iizuka N, Ogura Y, Yoshimura K et al. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo. Br J Cancer 1999; 80: 1420-1426.
29. He X, Li W, Wang Y, Hou L, Zhu L. Inhibition of colon tumor growth by IL-15 immunogene therapy. Mol Med Rep 2012; 5: 96-102.
30. Meazza R, Lollini PL, Nanni P, De Giovanni C, Gaggero A, Comes A et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 2000; 87: 574-581.
31. Tasaki K, Yoshida Y, Miyauchi M, Maeda T, Takenaga K, Kouzu T et al. Transduction of murine colon carcinoma cells with interleukin-15 gene induces antitumor effects in immunocompetent and immunocompromised hosts. Cancer Gene Ther 2000; 7: 255-261.
32. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8 +/CD44high T cells and its antitumor action. J Immunol 2008; 180: 2099-2106.
33. + memory cell pool. J Clin Invest 2005; 115: 1177-1187.
34. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000; 87: 186-194.
35. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-5142.
36. Ng P, Parks RJ, Cummings DT, Evelegh CM, Graham FL. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther 2000; 11: 693-699.
37. Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci USA 2008; 105: 3509-3514.
38. Rosato A, Dalla Santa S, Zoso A, Giacomelli S, Milan G, Macino B et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res 2003; 63: 2158-2163.
39. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007; 67: 1326-1334.
40. Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008; 16: 1609-1616.
41. Soman G, Yang X, Jiang H, Giardina S, Vyas V, Mitra G et al. MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. J Immunol Methods 2009; 348: 83-94.